All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Carfilzomib has been approved for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM) patients, that have received one to three prior lines of therapy. Data from both the ASPIRE and ENDEAVOR trials showed that patients receiving carfilzomib displayed a significant increase in both progression‐free survival (PFS) and overall survival (OS) compared to patients in the control groups who were treated with standard of care. However, a question that needs to be addressed is when treatment should be given in RRMM patients for maximum efficacy. Maria-Victoria Mateos, from the University Hospital Salamanca, Spain and colleagues, conducted post hoc analyses of data from both the ASPIRE and ENDEAVOR trials, in order to establish the difference in efficacy of carfilzomib in patients with either early or late relapse following their most recent therapy. The findings were published in Hematological Oncology in January 2018.
This study showed an improved PFS and ORR in patients who received carfilzomib as part of their treatment, regardless of either early or late relapse status. The results also suggested that patients with a late relapse, following the most recent prior line of therapy, had better clinical outcomes in comparison to patients with early relapse.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox